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SummAry – bladder carcinoma in situ (CiS) is a rare, high-grade intraepithelial neoplasm 
with a high tendency of progression and unpredictable clinical course. The aim of this study was to 
evaluate the incidence, treatment and clinical outcome of patients with CiS during a 10-year peri-
od. medical records of 1062 patients with primary bladder cancer and 847 patients with recurrent 
bladder cancer that underwent tumor resection at department of urology, Split university Hospital 
Center, Split, Croatia, between January 2001 and december 2010, were analyzed. Among all trea-
ted patients with primary bladder neoplasms, 51 (4.8%) had CiS. Primary CiS was diagnosed in 18 
(1.7%) and concomitant CiS in 33 (3.1%) patients. in the same period, 847 patients with recurrent 
tumors were treated by transurethral resection (tur), 12 (1.4%) of them with secondary CiS. 
Clinical course was followed-up in 15 patients with primary CiS and 21 patients with concomitant 
(tat1) CiS. bCg immunotherapy was applied in 12 patients with primary and 17 patients with 
concomitant CiS. After median follow-up of 50 months, 9 patients with primary CiS had no sign of 
disease, 4 progressed, 1 had recurrence and 1 died. After median follow-up of 37 months, 13 (62%) 
patients with concomitant CiS had complete response, 3 progressed (14%), 1 had recurrence (4%) 
and 4 patients died, however, only 2 (10%) of these due to bladder cancer. Of all patients receiving 
bCg immunotherapy, 8 (27%) had significant side effects. The incidence and treatment of patients 
with CiS of urinary bladder in our institution is comparable to other recent literature reports.
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Introduction
Carcinoma in situ (CiS) of urinary bladder is de-
fined as a noninvasive, flat, and high-grade cancerous 
lesion confined to the superficial lining of the bladder, 
composed exclusively of poorly differentiated, ana-
plastic cells. According to clinical manifestations and 
compared to papillary urothelial carcinomas, CiS can 
be primary, secondary and concomitant1. Primary tu-
mor is a lesion in the plane of mucosa in patients who 
previously had no urothelial malignancy. Secondary 
tumor occurs during evolution of previously treated 
urothelial cancer, while concomitant tumors are those 
that persist simultaneously with other forms of urothe-
lial cancer at the time of setting the initial diagnosis. 
it is estimated that 5%-10% of patients with urothelial 
cancer have some form of CiS1,2. Although CiS is a 
rare entity, it is important for two reasons. first, it is 
difficult to make the diagnosis of CiS because it is an 
intraepithelial lesion that can exist in the macroscopi-
cally normal mucosa. Another reason is the high ma-
lignant potential of untreated CiS, which progresses 
in 80%-100% of cases3,4. CiS is considered a precursor 
of muscle-invasive bladder tumors5,6.
relevant literature provides a significant number of 
articles analyzing CiS from various aspects. it should 
be pointed out that those were mainly retrospective 
202 Acta Clin Croat,  Vol. 51,   No. 2,  2012
d. librenjak et al. urinary bladder carcinoma in situ
studies with a relatively small number of patients and 
that a relatively small number of patients with CiS are 
recruited through multicenter studies. 
The aim of this study was to analyze the incidence, 
methods and results of treatment in patients with CiS 
of urinary bladder during a 10-year period at depart-




in this retrospective clinical study, we analyzed 
the incidence, methods and results of treatment in pa-
tients with CiS of urinary bladder during a 10-year 
period.
Setting
The study was conducted at department of urol-
ogy, Split university Hospital Center, Split, Croatia, 
between January 2001 and december 2010.
Patients
we analyzed medical records of 1909 patients 
operated for primary and recurrent bladder cancer 
(fig. 1). There were 1062 patients with primary blad-
der tumors who underwent tumor resection. Out of 
847 patients with recurrent tumors, 726 underwent 
transurethral resection (tur) biopsy for primary and 
recurrent bladder tumors during the study period, 
whereas 121 patients were treated by tur for pri-
mary tumor before the study period. Painless, unpro-
voked hematuria was the most common indication for 
conducting diagnostic work-up. information on the 
attributes of the tumor (number, size, localization, 
appearance, degree of malignancy and stage) were 
recorded from the history of the disease and surgical 
and histopathologic findings.
Diagnosis and therapy of CIS
diagnosis of primary CiS was made in patients 
with persistent irritation disorders of urination, dy-
suria, and asymptomatic microscopic hematuria. The 
Fig. 1. Flow chart: surgically treated patients with bladder cancer
CiS = carcinoma in situ; bCg = bacille Calmette-guérin; tat1 = non-muscle invasive 
bladder cancer; t2 = muscle invasive bladder cancer
































BCG           17









standard preoperative procedure includ-
ed intravenous pyelography (iVP), uri-
nary tract ultrasonography, urethrocys-
toscopy and cytologic analysis of urine 
sediment. The degree of malignancy 
was determined according to the world 
Health Organization classification from 
1998, and stage of disease according to 
tnm classification from 19977,8. 
Primary, secondary, concomitant 
CiS and non-muscle invasive bladder 
tumors were an indication for bCg im-
munotherapy. we applied Stamm-strain 
Cannaught immucyst (Cannaught lab-
oratories ltd., Ontario), 27 mg/ml, 
3x108 ml of live mycobacteria in 1 ml 
vaccine. before instillation, urinary tract 
infection was excluded and the catheter 
was introduced in an atraumatic way. 
Suspended vaccine (3 ml of the vaccine 
in 50 ml of saline) was administered 
through catheter into the bladder. Pa-
tients retain the fluid within the bladder 
for 2 h (30 min prone, 30 min supine and 
30 min on each side) to ensure that all 
bladder mucosa comes into contact with 
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bCg. we began therapy in the 3rd or 4th week after 
tur. 
Patient follow-up
The course of disease was determined by the re-
currence, progression (defined as muscle invasion) and 
lethal outcome. Patients were followed-up with cys-
toscopy and cytologic analysis of urine sediment every 
3 months during the first year after tur. later, the 
interval was successively extended to 6 months or 1 
year and iVP every 2-3 years, depending on the initial 
histopathologic findings.
Statistical methods
descriptive statistics was used for data presenta-
tion. data were presented as frequencies and percent-
ages, and medians where appropriate.
Results
during the 10-year study period, 1062 patients 
(819 men, 77%) with primary bladder cancer and 847 
patients (620 men, 73%) with recurrent tumors were 
operated on. in 1062 patients with primary urothelial 
cancers, CiS was noted in 51 (4.8%) patients. Primary 
CiS was diagnosed in 18 (1.7%) and concomitant CiS 
in 33 (3.1%) patients. Among 33 patients with concom-
itant CiS, there were 24 concomitant CiS with tat1 
tumors and 9 concomitant CiS with t2 tumors. in 847 
patients with recurrent urothelial tumors, secondary 
CiS was recorded in 12 (1.4%) patients (fig. 1).
Three of 18 patients with primary CiS failed to 
present for regular check-ups after surgery. we treated 
and followed-up 15 patients. in 12 patients, we applied 
intravesical bCg immunotherapy. we prefer South-
west Oncology group (SwOg) schedule in which 
after the induction dose of bCg instillation once 
weekly for 6 weeks, patients receive further courses of 
bCg as maintenance therapy: bCg instillations once 
a week for three weeks at 3, 6, 12, 18, 24, 30 and 36 
months after the initial course of bCg9.
This intense and prolonged schedule was fully ap-
plied in three patients and in a reduced form (due to 
side effects or lack of cooperation) in five patients. two 
patients received only 6 induction doses, whereas in 
two patients we used our original schedule: 6 weekly 
+ 6 monthly instillations10. in one patient, we applied 
doxorubicin (6 weekly doses) intravesically, while two 
patients refused bCg immunotherapy and were just 
followed-up.
After an average follow-up of 50 months, complete 
favorable response was recorded in nine (60%) pa-
tients, progression in four (26%) patients, and relapse 
and death in one (6%) patient each (table 2).
Table 1. Patients with primary carcinoma in situ
gender n Age (years) follow-up (months)
female 1 54 90
male 14 68 (42-80) 48 (6-114)
Table 3. Patients with concomitant carcinoma in situ
gender n Age (years) follow-up (months)
female 2 65.5 18.5
male 19 65 (46-79) 39 (12-92)
Table 2. Outcome in treated patients with primary carci-
noma in situ
n Cr P r death
bCg 12 9 1 1 1
doxorubicin 1 1
Just followed 2 1 1
bCg = bacille Calmette-guérin; Cr = complete response; P = pro-
gression; r = recurrence
Concomitant CiS with tat1 tumors were docu-
mented in 24 patients, but three of these patients 
failed to present for follow-up after the surgery, so we 
followed-up 21 patients (table 3).
bCg immunotherapy was applied in 17 patients, 
three were followed-up, and in one patient radical 
cystectomy was performed. SwOg schedule was 
used in 11 patients (complete in 3 and reduced form 
in 8 patients), whereas 6 weekly doses and 6 weekly 
+ 6 monthly instillations were administered in 3 pa-
tients each. After an average follow-up of 37 months, 
complete favorable response was recorded in 13 (62%) 
patients, progression in three (14%) patients, relapse 
in one (4%) patient, while four patients died (2 from 
bladder cancer, 10%) (table 4).
Significant side effects that warranted withdrawal 
of bCg immunotherapy were recorded in eight (27%) 
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patients. Seven patients experienced fever with dy-
suria, frequency and hematuria for several days. This 
condition was alleviated with supportive measures 
(adequate hydration, antipyretics, bed rest). Another 
patient became highly febrile after 15 instillations 
(SwOg scheme) and was hospitalized for hemo-
dynamic instability and threatening sepsis. gram-
negative bacteria were isolated from urine and blood 
and the patient was treated according to the antibiotic 
sensitivity report. After 7-day therapy that failed to 
produce any effect, we introduced ex juvantibus anti-
tuberculous drugs: isoniazid, rifampicin and ethamb-
utol. This therapy led to clinical improvement and pa-
tient recovery. The patient continued taking isoniazid 
and rifampicin for 3 months after leaving the hospital 
and at the time of the last follow-up did not exhibit 
clinical problems.
Of 12 patients with secondary CiS, in four pa-
tients CiS occurred during the evolution of primary 
muscle-invasive tumors, while in another eight pa-
tients CiS was recorded during monitoring of patients 
with tat1 tumors, who had previously received bCg 
immunotherapy. These patients were not included in 
the analysis.
Discussion
unlike other organs (testis, prostate) where CiS is 
considered a premalignant lesion, CiS of the urinary 
bladder is a clinically and histopathologically clearly 
defined entity11. it is featuring often unpredictable 
clinical course, with a significant malignant poten-
tial12. Since our patient cohort was small, with a total 
of 1183 patients operated on for bladder cancer, the 
absolute number of patients with CiS in our study was 
also small, especially those with primary CiS, which 
is relatively uncommon as a primary entity. However, 
we believe that this study adds useful data on the in-
cidence, treatment and clinical outcome of urinary 
bladder CiS in Split, Croatia. in Croatian urological 
literature, there are very few papers dealing with any 
aspect of urinary bladder CiS13.
we found that the diagnosis of primary CiS was 
established in patients whose symptoms were identi-
cal with benign conditions, such as interstitial cystitis 
and chronic prostatitis. in these cases, diagnosis can 
only be made if suspicion of a malignant disease aris-
es. diagnosis of CiS, including urine cytology, biopsy 
of bladder mucosa, is quick and easy.
diagnosis of concomitant CiS depends on how 
resection of bladder tumors is performed and on com-
petence of the pathologists. Properly performed resec-
tion of the tumor involves resection of tumor above the 
base, then the base of the tumor, and eventually the 
surrounding apparently normal mucosa (fractioned 
resection)14. taking biopsy material from apparently 
normal mucosa in different quadrants of the bladder 
is not considered obligatory, but there are divergent 
opinions about this15,16.
until 2000, CiS was diagnosed (pri-
mary or concomitant) at our department 
sporadically. Since 2000, we insist on 
fractioned resection (although not all 
urologists accept this way of tumor resec-
tion). Also, we intensified and improved 
communication with pathologists.
with regard to the character, i.e. 
multifocal, intraepithelial lesions that 
can persist on the macroscopically nor-
mal urothelium, CiS is a surgically un-
resectable disease. Therefore, tur alone 
is not adequate for control of the disease 
Table 4. Outcome in treated patients with concomitant 
carcinoma in situ
n Cr P r death
bCg 17 11 3 1+2*
Just followed-up 3 1 1 1
Cystectomy 1 1
bCg = bacille Calmette-guérin; Cr = complete response; P = pro-
gression; r = recurrence; *fatal outcome due to other reasons
Table 5. Literature data on the number of patients with primary 
carcinoma in situ 






Jakse et al., 200121 19 4 5
losa et al., 200022 21 8 1
gofrit et al., 200926 38 18 1
takenaka et al., 200825 69 6 16
griffiths et al., 200227 23 10 1
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and results in progression in 80%-100% of cases and 
specific mortality of 39%3,4,17.
Since 1976, when morales et al. first demonstrated 
that intravesical bCg vaccine could be applied to re-
duce the rate of recurrence of non-muscle invasive tu-
mors, bCg immunotherapy has established itself as 
an effective method in preventing recurrence and pro-
gression of non-muscle invasive tumors18. The indica-
tions for bCg immunotherapy are primary aggressive 
forms of non-muscle invasive tumors: t1g2-3, mul-
tiple, large, recurrent tag2 tumors and CiS. before 
the era of bCg immunotherapy, radical cystectomy 
was the method of choice in the treatment of CiS of 
the bladder19. According to the recommendations of 
the european Association of urology (eAu) from 
2011, bCg immunotherapy is considered the treat-
ment of choice for primary CiS20. However, this rec-
ommendation is based on only two studies with a rela-
tively small number of patients21,22. Jakse et al. applied 
6 weekly doses in 17 patients with primary CiS with 
an average follow-up at 7 years; complete response to 
therapy was recorded in 82% of patients, with no fa-
tal outcome16,19,21. losa et al. treated 21 patients with 
primary CiS; they applied the scheme with additional 
instillations (6 weekly + 12 monthly doses), but in a 
reduced manner. However, in their analysis, results 
were expressed for all forms of CiS (primary, second-
ary and concomitant). At 6-year follow-up, complete 
response was recorded in 93% of patients, but from 
these results we cannot read the results of treatment 
in patients with primary CiS only22.
Although accepted, the division of CiS into pri-
mary, secondary and concomitant is ignored in the 
vast majority of research publications and the results 
on all types of CiS are displayed together. Concomi-
tant CiS with t2 tumors is exempted, where muscle-
invasive tumor determines the course of treatment. 
we believe that the division of CiS is not only di-
dactic and formal, but patients with different forms 
of CiS do not have the same likelihood of successful 
disease control. when tur was the only treatment 
provided to patients with  primary CiS, progression 
was observed in 28% of cases, and in patients with 
concomitant and secondary CiS in 59% cases23,24.
Since primary and concomitant CiS are histo-
pathologically identical lesions, it is logical to assume 
that patients with concomitant carcinoma will have 
less favorable clinical course, which is significantly af-
fected by the attributes of tumor, such as stage, grade, 
number and size. in some studies, there is no differ-
ence in the response to bCg immunotherapy without 
maintenance between patients with different forms of 
CiS who had complete response in 63%-86% of cases, 
depending on the length of follow-up25,26. griffiths et 
al. applied 6 weekly doses and noted a statistically sig-
nificantly greater rate of progression in patients with 
concomitant CiS (t1) compared to those with pri-
mary or concomitant CiS with ta tumors27. in this 
study, the number of patients with concomitant CiS 
(t1) was significantly higher than in the previously 
mentioned works. losa et al. also noted a higher rate 
of progression in concomitant CiS (t1) in compari-
son to other forms22.
in our patients, we preferred the scheme with ad-
ditional instillations, referring to the meta-analysis 
of Sylvester et al. in which they showed that only a 
scheme with additional instillations could reduce the 
rate of progression in non-muscle invasive bladder 
cancer. This meta-analysis also clearly points out the 
superiority of bCg immunotherapy against intra-
vesical chemotherapy in treating non-muscle invasive 
urothelial bladder cancer28.
in our study, the incidence of urinary bladder pri-
mary CiS was low, only 1.7% of 1062 patients with 
primary urinary bladder cancer. This is in agreement 
with the current knowledge of bladder cancer and pre-
vious findings that primary CiS accounts for only 1%-
3% of all urothelial neoplasms29,30. Our patient cohort 
was small, but comparable to other recent publica-
tions on the issue, as shown in table 5. in multicenter 
studies, subjects are often recruited over a longer 
period of time, but the low number of patients with 
primary CiS certainly has an impact on the quality 
and credibility of statistical analysis. Our experience 
with bCg immunotherapy in the treatment of pri-
mary CiS is in agreement with literature data. After 
an average follow-up of 50 months, 94% of patients 
were alive, while 60% of patients had complete favor-
able response. These results confirm that bCg im-
munotherapy (schedules with additional instillations 
as maintenance therapy) is the method of choice in the 
treatment of primary CiS of urinary bladder.
According to the eAu recommendation from 
2011, the treatment of concomitant CiS with tat1 
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tumors is determined by therapeutic approach to 
tat1 tumors20. The eAu formulation is partially in-
accurate and incorrect. if we look at non-muscle in-
vasive tumors, concomitant CiS is usually associated 
with high grade t1 tumors in which bCg immuno-
therapy is certainly indicated and the indication areas 
for both forms of the tumor are matched. However, 
concomitant CiS can be found, although rarely, with 
g2 differentiated ta tumors, which can be monitored 
(small, solitary, primary) or we can indicate the use of 
intravesical chemotherapy. in these cases, the CiS is 
the form that determines the dominant therapy, which 
is the use of intravesical bCg immunotherapy.
The latest recommendations from eAu (June 
2011) include bCg immunotherapy as the treatment 
of choice for CiS if there is an intention to preserve 
the bladder with complete positive response rate of 
72%-93%29,30. This recommendation applies to all 
forms of CiS, which partially corrects the imprecision 
of previous guidelines. for now, there are no random-
ized, prospective studies comparing the effectiveness 
of bCg immunotherapy and early radical cystectomy 
in the treatment of CiS31.
despite the significant number and types of side 
effects that we recorded, we believe that our results 
justify the use of bCg immunotherapy in the treat-
ment of CiS of urinary bladder, in particular this 
schedule with additional instillations (maintenance 
therapy). follow-up of patients with urinary bladder 
CiS must be rigorous and lifelong because there is a 
significant risk of recurrence and progression in spite 
of appropriate treatment. in these cases, radical cys-
tectomy is indicated, depending on patient age and 
comorbidity.
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Sažetak
KArCinOm in Situ mOKrAćnOg mJeHurA: inCidenCiJA, liJeČenJe i KliniČKi iSHOd 
tiJeKOm deSetOgOdiŠnJeg PrAćenJA
D. Librenjak, Ž. Saratlija Novaković i K. Milostić
Karcinom in situ mokraćnog mjehura (CiS) je rijetka intraepitelijska neoplazija visokog stupnja s visokom tendenci-
jom progresije i teško predvidljivog kliničkog tijeka. Cilj ovoga istraživanja bila je evaluacija incidencije, liječenja i ishoda 
liječenja bolesnika s CiS-om tijekom 10-godišnjeg razdoblja. Analizirane su povijesti bolesti 1062 bolesnika s primarnim 
tumorima mokraćnog mjehura koji su podvrgnuti transuretralnoj resekciji (tur) na Odjelu za urologiju KbC Split izme-
đu siječnja 2001. i prosinca 2010. godine. Od svih bolesnika s primarnim tumorom mokraćnog mjehura koje smo liječili, 
51 (4.8%) ih je imalo CiS. Primarni CiS dijagnosticiran je u 18 (1.7%) bolesnika, a konkomitantni u 33 (3.1%) bolesnika. u 
istom razdoblju 847 bolesnika s recidivnim tumorima liječeno je tur-om, njih 12 (1.4%) sa sekundarnim CiS-om. Pratili 
smo klinički tijek 15 bolesnika s primarnim CiS-om i 21 bolesnika s konkomitantnim (tat1) CiS-om. bCg imunotera-
pija je primijenjena u 12 bolesnika s primarnim i u 17 bolesnika s konkomitantnim CiS-om. nakon medijana praćenja od 
50 mjeseci 9 bolesnika s primarnim CiS-om nije imalo znakove bolesti, u 4 je zabilježena progresija, u 1 recidiv i 1 bolesnik 
je umro. nakon medijana praćenja od 37 mjeseci među bolesnicima s konkomitantnim CiS-om 13 (62%) ih je bilo bez 
znakova bolesti, 3 je progrediralo (14%), u 1 je zabilježen recidiv (4%), 4 bolesnika su umrla, ali samo 2 zbog karcinoma 
mokraćnog mjehura (10%). Od svih bolesnika liječenih bCg imunoterapijom 8 (27%) ih je imalo značajnije nuspojave. 
incidencija i liječenje bolesnika s CiS-om mokraćnog mjehura u našoj ustanovi usporedivi su s rezultatima iz literature. 
Ključne riječi: Tumor mokraćnog mjehura; Karcinom in situ; BCG cjepivo; Ishod liječenja

